Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 1,641

Document Document Title
WO/2014/144737A1
The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutic...  
WO/2014/127815A1
The present invention relates to dihydropteridinones, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ...  
WO/2014/127816A1
The present invention relates to spiroheterocycl-dihydropyhmidines, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which int...  
WO/2014/102511A1
The invention relates to the use of a folate derivative for an in vitro assay of the folate in a sample such as a biological sample.  
WO/2014/101134A1
Provided are a folic acid derivative, a preparing method thereof, and a composition and a kit containing the folic acid derivative. The folic acid derivative is (R)-2-(2-(R)-3,4-dihydroxy-5-carbonyl-2,5-dihydrofuran)-2-hy droxyethyl-4-(6...  
WO/2013/135359A8
The present invention is directed to carrier systems comprising ether-lipids conjugated to one or more bioactive ligands and exposed on the surface of the carrier system for use in targeted delivery and/or antigen display systems. Option...  
WO/2013/018103A3
A process for the extraction of the B group of vitamins from a first plant matter is disclosed wherein, prior to the said extraction operation, the first plant matter is treated with a second plant matter comprising acidic compounds. The...  
WO/2014/041446A3
Provided are tetrahydrobiopterin compounds or their pharmaceutically acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. Also provided are pharmaceutical compositions comprising an effectiv...  
WO/2014/066772A1
This disclosure relates to processes and reagents for making diaryliodonium salts, which are useful for the preparation of fluorinated, iodinated, astatinated and radiofluorinated aromatic compounds.  
WO/2014/016740A3
An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a...  
WO/2014/011900A3
Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.  
WO/2014/020553A1
The present invention provides salts of Pralatrexate, in particular, sodium, lithium and potassium salts and their polymorphic forms, process for the preparation thereof, pharmaceutical compositions comprising these salts and at least on...  
WO/2014/016740A2
An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a...  
WO/2014/005194A1
The present invention provides a ligand which binds to MR1 wherein said binding results in binding of the MR1 to MAIT cells.  
WO/2013/177713A1
The specification relates to a process for preparation of an antifolate compound of formula 7, such as Pralatrexate. Also, disclosed are intermediates and processes for preparation of intermediates useful in the preparation of the antifo...  
WO/2013/179033A1
The invention relates to new pteridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g....  
WO/2013/170671A1
Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the f...  
WO/2013/168693A1
Provided is a method for producing sepiapterin, lactoylpterin, and tetrahydrolactoylpterin. Sepiapterin, lactoylpterin, and tetrahydrolactoylpterin are obtained at a good yield by the reaction formula.  
WO/2013/167653A1
The present invention is directed towards new 18 F- folate/antifolate analogue radiopharmaceuticals, wherein the phenyl group within folate structures has been replaced by an 18F- heterocycle, their precursors, a method of their preparat...  
WO/2013/164856A1
A process for preparation of 4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid and other key intermediates in synthesis of 10-propargyl-10-deazaaminopterin (Pralatrexate) and the intermediates thereof. The 10-propargyl-10-deazaa...  
WO/2013/152609A1
Disclosed is a method for synthesizing sapropterin dihydrochloride. The present invention reduces a synthesis route of the sapropterin dihydrochloride, introduces a tetrahydrofuran solution as a catalyst in an asymmetric synthesis manner...  
WO/2013/152608A1
Disclosed is a method for synthesizing sapropterin dihydrochloride. The present invention reduces a synthesis route of the sapropterin dihydrochloride, and resolves a racemate intermediate or an intermediage having a low antimer isomeris...  
WO/2013/135359A1
The present invention is directed to carrier systems comprising ether-lipids conjugated to one or more bioactive ligands and exposed on the surface of the carrier system for use in targeted delivery and/or antigen display systems. Option...  
WO/2013/122112A1
Provided is a prodrug of a therapeutically active organic compound having: an amino group, a cyclic amino group or a hydroxyl group in the molecule; and a 2-nitro-1-imidazole propionic acid. In particular, provided is a prodrug in which ...  
WO/2013/116238A1
Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as hepatitis B virus infection, tuberculosis and type 2 diabetes based upon the administration of CaFolate. In one embodiment is...  
WO/2013/107236A1
Disclosed is a crystal form of (6S)-5- methyltetrahydrofolate salt and a method for preparing same. The crystal form is: C form of the crystal form of (6S)-5- methyltetrahydrofolate calcium salt, the X-ray diffraction pattern thereof hav...  
WO/2013/109939A1
The invention provides methods for attaching drugs, dyes or radiolabels to bis-MTX. This method can be used to prepare bis-MTX analogs that can be used to deliver agents, such as nanoparticles, drugs, dyes or radiolabels, to cells.  
WO/2013/096800A1
Processes for preparing and purifying Pralatrexate are described in the present application, as well as intermediates in these processes, and salts and solid state forms of the Pralatrexate intermediates.  
WO/2013/066375A1
Disclosed are methods for rapidly repleting folate levels of a woman for whom there is reason to believe that she may be pregnant or of a woman who believes that she may soon become pregnant. One of the methods includes administering to ...  
WO/2012/061469A3
This patent application provides crystalline forms of Pralatrexate, in particular, Form A, Form B and Form C, pharmaceutical compositions comprising a crystalline form of Pralatrexate and at least one pharmaceutically acceptable excipien...  
WO/2013/037957A1
The present invention relates to a method for purifying a gallium Ga68-radiolabeled contrast medium including a gallium Ga68-radiolabeled chelate vectorized by a folate or folate-derivative targeting ligand, the method including the foll...  
WO/2013/024035A1
The present invention is directed towards new trifunctional folate-conjugates comprising a folate, an albumin binder and a radionuclide-based therapeutic or diagnostic moiety as well as pharmaceutical compositions thereof, their method o...  
WO/2013/025203A1
A process of preparing (6S)-tetrahydrofolic acid derivatives comprising reacting racemic (6RS)-tetrahydrofolic acid derivatives with N-alkyl-D-glucamine, forming N-alkyl-D-glucamine salts of the (6RS)-tetrahydrofolic acid derivatives, is...  
WO/2013/018103A2
A process for the extraction of the B group of vitamins from a first plant matter is disclosed wherein, prior to the said extraction operation, the first plant matter is treated with a second plant matter comprising acidic compounds. The...  
WO/2012/175729A1
The invention relates to 10H-benzo[g]pteridine-2,4-dione derivatives, to the production thereof, and to the use thereof.  
WO/2012/175730A1
The invention relates to 10H-benzo[g]pteridine-2,4-dione derivatives, to the production thereof, and to the use thereof.  
WO/2012/074496A1
A new method for producing antifolate agents having glutamic acid part in their structure is developed by protecting carboxyl groups of glutamic acid or its N-subsituted derivatives as cyanomethyl ester to give compounds of formula (II) ...  
WO/2012/064674A1
Methods of assaying for (i) a pterin by immunoassay employing a pterin as capture agent, (ii) neopterin by chemiluminescent microparticle immunoassay (CMIA) employing an anti-neopterin antibody (Ab) as capture agent, (iii) neopterin by a...  
WO/2012/048451A1
A preparation process of (6R)-tetrahydrobiopterin hydrochloride is provided, which comprises hydrogenating L-biopterin in the presence of a catalyst of Pt group metal in the basic substrate containing solvent, potassium hydroxide and pot...  
WO/2012/049153A1
The present invention relates to an improved process for manufacturing dihydropteridinones of general formula (12) as well as intermediates thereof, wherein the groups R1, R2, R3, R4, and R5 have the meanings given in the claims and spec...  
WO/2011/159471A3
The disclosure provides linked purine pterin compounds and analogues thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula I: (I). ...  
WO/2011/157388A8
The application discloses a process for the preparation of 5-deoxy-L-arabinose of formula (VI); comprising the conversion of a compound of formula (XII); wherein n is 0, 1 or 2; which can be used as intermediate for the synthesis of sapr...  
WO/2012/011591A1
Disclosed is a compound that has excellent pharmacological activity, physicochemical qualities, and the like, and is useful in the prevention/treatment of eicosanoid-related conditions including arteriosclerosis, diabetes, obesity, ather...  
WO/2011/157388A1
The application discloses a process for the preparation of 5-deoxy-L-arabinose of formula (VI); comprising the conversion of a compound of formula (XII); wherein n is 0, 1 or 2; which can be used as intermediate for the synthesis of sapr...  
WO/2011/156889A1
There is provided modulators of Nrf2 protein which comprises a compound which binds at least one of the BTB domain, IVR domain and Kelch domain of Keap1 protein, activating or inhibiting Nrf2. There is also provided pharmaceutical compos...  
WO/2011/159471A2
The disclosure provides linked purine pterin compounds and analogues thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula I: (I). ...  
WO/2011/145068A1
The present invention relates to a compound of general formula (I) in which: - X is OH, NH2, NHOH or RNH, wherein R may be a linear or branched, saturated or unsaturated, C1-C10 alkyl radical, - Y is H, or an electron-withdrawing group, ...  
WO/2011/132435A1
Disclosed is a means for improving the symptoms of a cerebral dysfunction. The present inventors made a new discovery that the activity of brain aromatic monoamines increases when sepiapterin is administered peripherally. Disclosed, ther...  
WO/2011/113293A1
Dihydropteridinone derivatives, preparation method and pharmaceutical use thereof are disclosed. Specifically, disclosed are new dihydropteridinone derivatives represented by general formula (I), their preparation method, pharmaceutical ...  
WO/2011/101369A1
The present invention relates to new dihydropteridinones of general formula (12) wherein the groups R1 to R5 and L, n, and m have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihy...  

Matches 101 - 150 out of 1,641